Filing Flows

Filing Flows › 8-K events › Senti Biosciences Holdings

Senti Biosciences Holdings: departure or appointment of directors and officers

Form 8-K filed Oct 27, 2026 · items 5.02, 8.01

What the filing says

On October 27, 2026, Edward Mathers notified the Board of Directors (the "Board") of Senti Biosciences Holdings, Inc. (the "Company") of his decision to resign from the Board, effective immediately. In connection with his resignation from the Board, Mr.

Read the filing on SEC EDGAR →

What usually followsAcross 39,174 8-Ks reporting Item 5.02 (directors and officers: departures, appointments, pay) in our universe, the stock's median move the next session was −0.1% (typical size ±1.4%, up 48% of the time); over the following 21 sessions, +0.7%. Item 8.01: +0.1% next session across 44,881. Every item ranked →

What this kind of filing means

Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.

Senti Biosciences Holdings at a glance

Latest quarterQ2 2026
Revenue$17K
Operating marginn/m
IndustryBiological Products, (No Diagnostic Substances)

Senti Biosciences Holdings, Q2 2026: revenue $17K. The chart follows the revenue to costs, profit and cash.

Senti Biosciences Holdings: every quarter, Q/Q and Y/Y, holders and guidance →

Senti Biosciences Holdings’s other material 8-Ks

Other recent mergers and acquisitions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.